Glaxosmithkline | GSK - Selling And Administration Expenses



Glaxosmithkline reported GBP2.09B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Amgen USD 1.69B 4M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Aurora Cannabis CAD 45.63M 7.45M Jun/2025
Bausch Health Companies USD 894M 27M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Canopy Growth CAD 40.12M 504K Jun/2025
Corcept Therapeutics USD 103.85M 13.19M Jun/2025
Drreddys Laboratories INR 23.18B 1.59B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
J&J USD 5.89B 777M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Prestige Brands USD 28.46M 35.6M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
Takeda JPY 255.89B 39.98B Jun/2025
Teva Pharmaceutical Industries USD 959M 40M Jun/2025
Zoetis USD 617M 54M Jun/2025